- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02830919
Clinical Study of Non-inferiority With Participants Diagnosed With Primary Knee OA (GLACIAL) (GLACIAL)
October 8, 2019 updated by: Eurofarma Laboratorios S.A.
Phase III Clinical Study, Multicenter, Randomized, Single-blind, Parallel Groups for Safety Evaluation and Non-inferiority of Efficacy of Glucosamine Sulfate Plus Chondroitin Sulfate From Bovine Origin (Eurofarma Laboratorios S.A.) Versus Condroflex ® in the Treatment of Symptomatic Knee Primary Osteoarthritis
This phase III clinical study will be conducted in Brazilian research sites.
It will be included in the study 314 participants diagnosed with primary knee OA according to the classification criteria of the ACR.
After a washout period, the participants will be randomized to receive the combination of glucosamine sulfate + chondroitin sulfate of bovine origin of Eurofarma Laboratorios S.A. (N= 157) or the combination of glucosamine sulfate + chondroitin sulfate of Zodiac Pharmaceuticals S.A. Condroflex ® (N = 157).
The treatment period of the study will be of 24 weeks.
Each participant will perform seven visits to the research site.
The main evaluations will be the improve of pain in the target knee by questionnaire Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and quality of life by SF-12 questionnaire.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
627
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Goiás
-
Goiânia, Goiás, Brazil
-
-
PR
-
Curitiba, PR, Brazil
-
-
Paraná
-
Maringá, Paraná, Brazil
-
-
SP
-
São Paulo, SP, Brazil
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Male and female patients meeting all the following criteria will be enrolled in the study:
- Aged ≥ 40 years.
- Clinical and radiological diagnosis of primary (idiopathic) arthrosis of knee according to the criteria of the American College of Rheumatology (ACR).
- Kellgren and Lawrence radiological classification of degree 2 or 3 in x-ray of knee-target obtained in 3 months prior to the screening visit of the study.
- Presence of painful symptoms in the target knee in the last 3 months due to osteoarthritis.
- Visual analogue scale for evaluation of the pain of osteoarthritis of knee by the research participant in the screening visit ≥ 40 mm
- Average score ≥ 40 mm in the subscale of "pain" (from 0 to 100 mm) in the target knee of the questionnaire Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), in the randomization visit.
- Functional class ACR from I to III.
- Signing the Informed Consent Form (ICF) before the performance of any study procedure.
Exclusion Criteria:
Patients meeting at least one of the following criteria will be excluded from the study:
- Diagnosis of septic arthritis, inflammatory arthritis (as rheumatoid arthritis), gout, pseudogout, Paget's disease, dysplasias or congenital joint abnormalities.
- Presence of inflammatory signals (edema, erythema or joint effusion) in the target knee, considered to be clinically significant by investigator.
- Serious target knee joint misalignment, defined by investigator.
- Predominantly patellofemoral Osteoarthritis in the target knee.
- Historical of severe trauma or surgery (including arthroscopy) in the target knee in the 6 months before the screening visit.
- Planned Surgery to the target knee
- Symptomatic Osteoarthritis of the ipsilateral hip.
- Use of non-steroidal anti-inflammatory, dipyrone and opioid analgesics or narcotics from the screening visit, or a washout period for these medicines less than those defined by the Protocol, before the randomization visit .
- Oral Glucocorticoids, intravenously or intramuscularly in the 30 days prior to the screening visit.
- Intraarticular corticosteroid Injection and/or hyaluronic acid in the target knee in 6 months prior to the screening visit.
Use of the following drugs in the periods described below, before the screening visit:
- Diacerein, chloroquine or soybean and avocado unsaponifiables extracts in the last 3 months.
- Duloxetine hydrochloride in the last 30 days.
- Glucosamine Sulphate and/or chondroitin sulfate in the last 6 months.
- Strontium ranelate for the past 6 months.
- Historical of allergy or intolerance to treatment of the study or to paracetamol.
- Physiotherapy or irregular practice of physical activity beginning in the 3 months prior to the screening visit.
- Diagnosis of fibromyalgia, collagenosis or significative vascular/neurologica diseases in lower limbs that may confuse the analysis of the study.
- Body mass index ≥ 40 kg/m2.
- Need to use cane, crutches or a walker.
- Presence of infectious hepatitis active or history of hepatitis medicinal products.
- Results of ALT, AST and total bilirubin and fractions above the upper limit of normal.
- Serum creatinine level above the upper limit of normal.
- Fasting blood glucose > 110 mg/dL or glycated hemoglobin > 6.5%.
- Use of anticoagulants.
- Consumption of alcohol more than one dose a day (women) or two doses a day (men).
- Presence of serious diseases or not controlled.
- Planned surgery to occur during the period of participation in the study.
- Presence of pregnancy or breastfeeding.
- Women of childbearing potential must agree to use highly effective contraception.
- Participation in a clinical trial protocol within the previous 12 months unless, at the investigator's discretion, his or her participation may imply a direct benefit for the participant.
- Presence of any condition which, at the investigator's discretion, may consider the participation of the patient inadequate for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Glucosamine and chondroitin sulfate combination (Eurofarma)
Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Eurofarma Laboratórios S.A., administered once a day for 24 weeks.
|
|
Active Comparator: Glucosamine and chondroitin sulfate combination (Zodiac)
Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Zodiac Produtos Farmacêuticos S.A. (Condroflex®), administered once a day for 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absolute change of pain WOMAC subscale score 24 weeks after initiation of treatment.
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absolute change the overall assessment of the disease by the investigator along treatment as measured by Visual Analog Scale from 0 to 100mm.
Time Frame: 24 weeks
|
24 weeks
|
Absolute change score of physical and mental components of the questionnaire SF-12 24 weeks after initiation of treatment compared to baseline.
Time Frame: 24 weeks
|
24 weeks
|
Incidence and profile of adverse events coded as MedDRA by treatment group.
Time Frame: 24 weeks
|
24 weeks
|
Frequency of treatment discontinuation for adverse events and laboratory abnormalities.
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 5, 2016
Primary Completion (Actual)
May 10, 2019
Study Completion (Actual)
May 10, 2019
Study Registration Dates
First Submitted
July 7, 2016
First Submitted That Met QC Criteria
July 8, 2016
First Posted (Estimate)
July 13, 2016
Study Record Updates
Last Update Posted (Actual)
October 9, 2019
Last Update Submitted That Met QC Criteria
October 8, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EF140
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis of Knee
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
CrystalGenomics, Inc.CompletedLocalized Primary Osteoarthritis of Hip | Localized Primary Osteoarthritis of KneeKorea, Republic of
-
zhoupingBeijing Friendship Hospital; Beijing Jishuitan HospitalUnknownOsteoarthritis Of KneeChina
-
Universidade Nova de LisboaHospital de Santa Maria, Portugal; NOVA Medical School; Hospital de Egas Moniz; Instituto de Medicina Molecular João Lobo Antunes and other collaboratorsUnknown
-
Ottawa Hospital Research InstituteCompleted
-
Hospices Civils de LyonSmith & Nephew, Inc.Completed
-
First Affiliated Hospital of Harbin Medical UniversityShanghai Baiying Medical Technology Co., Ltd.UnknownOsteoarthritis Of KneeChina
-
Stempeutics Research Pvt LtdStempeutics Research Malaysia SDN BHDCompleted
-
Government Medical College, BhavnagarCompletedOsteoarthritis of Knee JointIndia
-
GCS Ramsay Santé pour l'Enseignement et la RechercheRecruitingUnilateral Primary Osteoarthritis of KneeFrance
Clinical Trials on Glucosamine and chondroitin sulfate combination (Eurofarma)
-
Dawn L. HershmanCompletedBreast Cancer | Joint PainUnited States
-
Azidus BrasilCompleted
-
Tedec-Meiji Farma, S.A.Completed
-
Mantecorp Industria Quimica e Farmaceutica Ltd.Unknown
-
Eurofarma Laboratorios S.A.Withdrawn
-
Ache Laboratorios Farmaceuticos S.A.Completed
-
University of SydneyNational Health and Medical Research Council, AustraliaUnknown
-
Azidus BrasilUnknown
-
Unipharm, Inc.CompletedLow Back PainRussian Federation
-
Fred Hutchinson Cancer CenterCompletedHealthy SubjectUnited States